Rep. Kevin Hern (R-OK) Sells STERIS (STE) Stock

Oklahoma Congressman Kevin Hern sold shares of STERIS plc (STE) on September 15, 2026, valued between $15,001 and $50,000. The transaction was disclosed on September 25, 2026, and took place while STERIS shares were priced at $221.43.

Inside Kevin Hern's Trade

Hern, a Republican representing Oklahoma's 1st congressional district in the House, sold shares of STERIS but did not disclose the exact number. The reported value suggests a significant stake, reflecting a potential strategy shift or reallocation of assets.

Other Institutional Activity in STERIS

Several institutional investors have adjusted their positions in STERIS recently. BlackRock Inc. reduced its holdings by 205,809 shares, ending with 8,820,889 shares worth about $1.96 billion. Vanguard Capital Management LLC increased its stake by 40,743 shares, bringing its total to 6,406,906 shares valued at approximately $1.42 billion. State Street Corporation grew its holdings by 80,870 shares to 5,072,818 shares, worth about $1.12 billion.

STERIS plc Stock Down 1.3%

STERIS shares are currently trading at $221.43, which is close to their 52-week low of $195.14. The stock has struggled to maintain upward momentum, especially considering its previous close of $205.04. The company has a P/E ratio of 25.30, indicating how much investors are willing to pay for $1 of earnings.

Recent Earnings

In its latest financial report, STERIS posted annual revenue of $6.04 billion, reflecting a growth rate of 7.3%. The company had a net margin of 13.33% and an ROE of 11.39%, showing solid financial health. The next earnings report is scheduled for November 4, 2026.

Analysts Set New Price Targets

Analysts have been optimistic about STERIS, with UBS maintaining a Buy rating and a price target of $270.00 as of August 7, 2026. Piper Sandler also reiterated an Overweight rating with a target of $275.00 on the same date. The consensus among analysts is a Buy rating, with a mean target price of $263.13 based on eight opinions.

About STERIS plc

STERIS plc specializes in providing infection prevention products and services globally, particularly in the healthcare and life sciences sectors. The company's diverse offerings are crucial for maintaining safety and cleanliness in medical environments, which is especially relevant amid ongoing health challenges.

Bottom Line

Watch for STERIS's upcoming earnings report on November 4, 2026, for insights into its recent performance. This transaction by Congressman Hern reflects strategic moves that may influence his future investments. Remember, the 13F filing system captures past holdings, which might not represent current positions.